Evidence map›Paper›PMID 36399953›Full record

SynthesisESMO open2022

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.

V Di Lauro, G Barchiesi, F Martorana, G Zucchini, M Muratore, C Fontanella, G Arpino, L Del Mastro, M Giuliano, F Puglisi and 1 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Clinical Implications ofPharmaceutics · 2026
    Review
  9. Review
  10. Review
  11. Observational
  12. Article
  13. CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  14. Observational
  15. Exploring the real-world experience of abemaciclib treatment for HR +, HER2 - metastatic breast cancer-a qualitative analysis of the IMPACTOR study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

V Di LauroDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples.
G BarchiesiDepartment of Radiology, Oncology and Pathology Science, University of Rome La Sapienza, Rome.
F MartoranaDepartment of Clinical and Experimental Medicine, University of Catania, Catania. Electronic address: federica.martorana@phd.unict.it.
G ZucchiniOncology Department, Michele e Pietro Ferrero Hospital, Verduno (CN).
M MuratoreDepartment of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.
C FontanellaOncology Unit, AULSS 1 Dolomiti, Belluno.
G ArpinoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples.
L Del MastroDepartment of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa.
M GiulianoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples.
F PuglisiDepartment of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano; Department of Medicine (DAME), University of Udine, Udine, Italy.
M De LaurentiisDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Naples Federico II · ITAgostino Gemelli University Polyclinic · ITBells University of Technology · NGCentro di Riferimento Oncologico · ITFerro (United States) · USOspedale Policlinico San Martino · ITSapienza University of Rome · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available.

methodsWe systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib.

resultsA total of 533 full-length articles and 143 abstracts were retrieved. After screening for eligibility, 38 records were included (31 clinical trials; 7 real-world reports). Assessment methods were heterogeneous across studies in terms of questionnaires, evaluation timepoints and endpoints. Overall, adding CDK4/6i to endocrine therapy did not worsen patients' HR-QoL, with a positive trend towards pain improvement. Gastrointestinal scores (diarrhea, nausea and appetite loss) statistically favored the control arm among metastatic BC patients receiving abemaciclib, whereas they were superimposable in the early setting. The combination of palbociclib and endocrine therapy showed similar HR-QoL outcomes compared with endocrine therapy alone, but determined better scores compared with chemotherapy. HR-QoL was specifically assessed in premenopausal patients treated with ribociclib, showing similar scores compared with postmenopausal patients.

conclusionsDespite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice.

Indexed as

Breast NeoplasmsProtein Kinase InhibitorsQuality of LifeAminopyridinesBenzimidazolesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansPurinesabemaciclibAminopyridinesBenzimidazolesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPurinesribociclibabemaciclibcyclin-dependent 4/6 inhibitorshealth-related quality of lifepalbociclibribociclib

Identifiers

PMID36399953
PMCPMC9808450
OpenAlexW4309341610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.